COX-2 inhibitors in prostate cancer treatmenthold your horses?

Abstract

Cyclo-oxygenase has been implicated as a potential therapeutic target in prostate cancer. However, the ongoing multi-arm randomized controlled STAMPEDE trial has failed to show a benefit of the cyclo-oxygenase 2 inhibitor celecoxib in men with locally advanced or metastatic prostate cancer also receiving androgen deprivation therapy. STAMPEDE uses a novel adaptive design that allows testing of different therapeutic interventions, and should generate much needed novel information regarding evidence-based prostate cancer management. © 2012 AJA, SIMM & SJTU. All rights reserved.